The All Wales Medicines Strategy Group (AWMSG) has recommended Bayer Healthcare’s Sativex Oromucosal Spray for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS).
Sativex Oromucosal Spray, which is recommended by NHS Wales, UK, is derived from whole plant extracts from the cannabis sativa plant and contains both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Commenting on the recommendation, Neath Port Talbot Hospital Rehabilitation Medicine consultant Dr Sajida Javaid said: "The AWMSG’s recognition of the value of Sativex is a significant milestone for the treatment of spasticity.
"Improved access to Sativex has been long awaited by clinicians and patients since its launch in 2010, so it is encouraging to see that patients in Wales will now have improved access to a treatment that has been proven to provide significant relief from the spasms and cramps associated with spasticity."
AWMSG has recommended Sativex as a treatment for adult patients who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
The prescription-only Sativex has to be sprayed on to different sites of the oromucosal surface, changing the application site each time it is used, according to Bayer.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSativex was shown to provide significant improvement in the 0-10 numeric rating scale (NRS) spasticity score and spasm frequency, compared with a placebo, in the phase III clinical trial.
